Hanbury FZE
  • Search
  • Home
  • Products & Services
    • Nutraceutical Ingredients
      • Standardized Phyto Extracts
      • Beverage/Liquid Dietary Supplements
      • GRAS Affirmed Ingredients
      • Minerals for Nutritional Use
      • Phytochemicals for Nutritional Use
      • Multi-enzyme Blends
      • Natural Protein
      • Nutritional Fine Chemicals
      • Phyto Functional Blends
      • Geroceuticals™
      • Prebiotics, Probiotics, Postbiotics and Synbiotics
      • Super Critical Fluid (SCF) Extracts
      • Specialty Fine Chemicals
    • Cosmeceutical Ingredients
      • Natural Actives
      • Peptides
      • Anti-Glycation
      • Dermaceuticals
      • Nutricosmetics
      • Probiotics & Postbiotics
      • Proprietary Cosmeceutical Blends
      • Speciality Chemicals
    • Services
      • Custom Manufacturing
      • Contract Manufacturing
      • Product Specification Sheet
    • Pharma
      • Natural Drugs
      • Chiral Drug Intermediates
  • About Us
    • Our Story
    • Our People
    • Research & Development
    • Manufacturing Facilities
    • Intellectual Properties
  • Newsroom
    • Press Release
    • FAQs
      • BioPerine®
      • Citrin®K
      • Cococin™
      • Curcumin C3 Complex®
      • Curcumin C3 Reduct®
      • ForsLean®
      • GarCitrin®
      • LactoSpore®
      • LeanGard®
  • Contact Us

Home / Sabinsa successfully protects its Curcumin C3 Reduct® technology

Sabinsa successfully protects its Curcumin C3 Reduct® technology

Sabinsa successfully protects its Curcumin C3 Reduct® technology

Sabinsa Corporation announced today that it has successfully concluded its Patent Infringement lawsuit against Olive Lifesciences Pvt. Ltd. On April 5, 2018, the United States District Court in New Jersey entered an judgment awarding Sabinsa over $850,000 in damages, enhanced damages, attorney’s fees, costs, and interest.

On June 8, 2016, Sabinsa filed suit against Olive for willful infringement of U.S. Patent No. 6,653,327, according to Sabinsa founder Dr. Muhammed Majeed. The ’327 Patent protects Sabinsa’s novel methods and formulations for tetrahydrocurcuminoids (THCs).

The judgment concludes that the ’327 Patent is valid, enforceable, and properly issued by the U.S. Patent and Trademark Office. Sabinsa has patents related to THCs in the United States, Europe, Australia, New Zealand, and other locations. In the United States, Sabinsa has successfully litigated willful infringement of the ’327 patent and has obtained judgments against other infringers.

Sabinsa has a well-earned reputation for strong enforcement of its intellectual property rights and will continue to pursue all available legal remedies to protect those rights, Dr. Majeed stated. “As a pioneer in the industry, Sabinsa has researched and developed many innovative products used by the nutritional supplement industry,” said Dr. Majeed. “The success has spawned many imitators, and Sabinsa will not hesitate to enforce its patents and other intellectual property,” he continued.

“We are very proud of our long-term partnership with Sabinsa to make sure that its intellectual property is enforced and respected in the industry,” added James H. Hulme, Sabinsa’s counsel. “Sabinsa can now point to a string of patent victories after this latest judgment,” Mr. Hulme said.

Sabinsa, which has pioneered the introduction of several herbal extracts in the U.S. market, is an application-oriented manufacturing and marketing company which manufacturers herbal extracts and specialty fine chemicals used for nutritional, pharmaceutical, cosmeceutical, and food products. Sabinsa distinguishes itself with its extensive research support for its customers and products, and the scientific credentials of its key technical staff.

Curcumin C3 Reduct® is a Registered Trademark and Patented product of Sabinsa Corp., and is protected under U.S. Patent No. 6,653,327, and International Patents. This ingredient provides many of the benefits of Sabinsa’s Curcumin C3 Complex® in a colorless, non-staining form.

Back
top

HEADQUARTERS

Hanbury FZE


Jebel Ali Free Zone


Warehouse No. RA08AB05


P O Box. 61091


Dubai


United Arab Emirates


+971 4 883 8981

+971 4 883 8978

mail@hanburyfze.ae

CERTIFICATES

Certificate Logos Certificate Logos Certificate LogosCertificate Logos

Global Contacts List

USA India
Utah, USA Japan
Australia Poland
Brasil Korea
Canada South Africa
China Vietnam
Germany  

CONTACT US

    © 2023 Hanbury FZE. All Rights Reserved | Powered by Edkal Technologies | Privacy Policy | Terms of Use | Sitemap | Disclaimer

    • Facebook
    • Twitter
    • LinkedIn
    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.